Disc Medicine, Inc. (IRON)
| Previous close | 30.36 |
| Open | 30.81 |
| Bid | 31.52 x 200 |
| Ask | 31.98 x 200 |
| Day's range | 30.81 - 32.18 |
| 52-week range | 25.60 - 77.60 |
| Volume | |
| Avg. volume | 493,583 |
| Market cap | 784.667M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 57.33 |
GlobeNewswireDisc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Monday, May 20th at 10:30 am ET. A live webcast of the fireside chat will be available through the
- GuruFocus.com
Disc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial Overview
Aligns Closely With Analyst Projections Amidst Strategic Clinical Advancements
- GlobeNewswire
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and AURORA in Q2 2024Plan to present updated data from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF), as well as initial single-ascending dose (SAD) data from the phase 1 study of DISC-3405 in healthy volunteers in Q2 2024Continue to be well-capitalized, ending Q1 2024 with $343M in cash
